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Abstract 
Short chain fatty acids (SCFA) are produced by the gut microflora following the intake of 
complex carbohydrates and have been suggested as a contributor for some of the health 
benefits associated with dietary fibre (DF) intake. For further research of the mechanisms 
and effects of SCFA, reliable and accurate methods for analysis of SCFA in different bio-
logical samples are needed. In this project the aim was to develop and validate a rapid and 
ease-of use method for analysis of SCFA content in faecal samples. The contents of acetic, 
propionic, iso-butyric, n-butyric, iso-valeric, n-valeric and capronic acid were analysed 
through a method where fecal water was obtained through centrifugation and SCFA were 
further extracted with propyl formate. Extracts were analysed on a gas chromatograph 
coupled with a flame-ionization detector (GC-FID). The method was validated including 
estimation of accuracy and precision which were measured through calculation of recov-
ery, deviation from linearity and by the coefficient of variance (CV), respectively. An 
exploratory test was also performed to analyse the distribution of SCFA in faecal matter. 
Moreover, the method was used to analyse SCFA concentrations in faecal samples (n=40) 
from two Norwegian bowel cancer projects, NORCCAP and BCSN. The results of the 
validation (recovery, CV and deviation from linearity) varied somewhat between the three 
batches, and thereby also the limits of quantification (LOQ), which were limited, but in 
most cases included the physiologically relevant concentrations. Through the exploratory 
distribution test, a significant difference in SCFA content was found between the in- and 
outside of the faecal sample, which emphasises the importance of homogenization of sam-
ples or consistent sampling from faecal samples. SCFA contents of faecal samples from 
the NORCCAP and BCSN samples were consistent with those reported by other studies, 
which indicate that the method produces reliable results. For a higher accuracy and preci-
sion, it is suggested that the amount of faecal material analysed is increased, followed by 
further validation of both lower and higher concentrations. Additionally, the effects of 
storage with and without buffer should also be investigated for more comparable results. 
 
Keywords: short chain fatty acids, SCFA, faeces, dietary fibre, quantification, gas chroma-
tography, flame ionization detector, GC-FID. 
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Sammanfattning 
Kortkedjiga fettsyror produceras av tarmfloran efter intag av komplexa kolhydrater och har 
föreslagits som en bidragande förklaring till några av de hälsofördelar som förknippats 
med intag av kostfibrer.  För vidare studier kring mekanismerna och effekterna av kort-
kedjiga fettsyror krävs pålitliga och precisa metoder för analys av kortkedjiga fettsyror i 
olika biologiska prover. I detta projekt var syftet att utveckla och validera en enkel och 
snabb metod för analys av kortkedjiga fettsyror i avföringsprover. Innehållet av ättik-, 
propan-, isobutan-, butan-, isovalerian-, valerian- och kapronsyra analyserades genom 
centrifugering, extrahering med propylformat och analys med gaskromatografi och flam-
jonisationsdetektor (GC-FID). Metoden validerades genom mätning av noggrannhet och 
precision som räknades ut i form av utbyte, avvikelse från standardlinje och variationsko-
efficient (CV). Ett ytterligare test utfördes för att undersöka hur koncentrationen av kort-
kedjiga fettsyror varierade i olika delar av ett avföringsprov. Dessutom användes metoden 
för att analysera innehållet av kortkedjiga fettsyror i prover (n=40) från två norska 
tarmcancer-projekt, NORCCAP och BCSN. Resultaten från valideringen (utbyte, variat-
ionskoefficient och avvikelse från standardlinjen) varierade mellan de tre omgångarna och 
därmed även gränserna för kvantifiering, vilka var begränsade men i de flesta fallen inklu-
derade de koncentrationer av kortkedjiga fettsyror som är fysiologiskt relevanta. Testet 
som undersökte variationen av kortkedjiga fettsyror uppvisade signifikanta skillnader mel-
lan in- och utsidan av avföringsprovet, vilket understryker vikten av homogenisering av 
prover och att vara konsekvent vid provtagning av avföringsprover. De koncentrationer 
som uppmättes från NORCCAP- och BCSN- proverna stämde väl överens med de som 
rapporterats i tidigare studier, vilket indikerar att metoden ger tillförlitliga resultat. För att 
uppnå högre precision och noggrannhet bör mängden avföring som analyseras ökas samt 
en ytterligare validering på både lägre och högre koncentrationer utföras. Dessutom bör 
effekterna av lagring med och utan buffert undersökas för mer jämförbara resultat. 
 
Nyckelord: kortkedjiga fettsyror, avföring, kostfibrer, kvantifiering, gaskromatografi, flam-
jonisationsdetektor. 
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Abbreviations 
CV Coefficient of Variance 
DF Dietary Fibre 
FID Flame Ionization Detector 
GC Gas Chromatography 
IS Internal Standard 
LC-MS Liquid Chromatography Mass Spectrometry 
LLOQ Lower Limit of Quantification 
LOQ Limit of Quantification 
MS Mass Spectrometry 
SCFA Short Chain Fatty Acids 
ULOQ Upper Limit of Quantification 
  
ace Acetic acid* 
pro Propionic acid* 
ibut iso-Butyric acid* 
but n-Butyric acid* 
ival iso-Valeric acid* 
val n-Valeric acid* 
cap Caproic acid* 
* For the sake of simplicity, the acid name will be used for all short chain fatty acids throughout 
the thesis, even though they in practice may occur in their ion form during some instances. 
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1 Introduction 
1.1 Dietary fibre and health 
Cases of non-communicable diseases, chronic diseases which are not transferred 
from person to person, are increasing and are today the most common causes of 
death worldwide (WHO, 2014). Cardiovascular disease and different cancers rep-
resent 60% of the deaths caused by non-communicable diseases worldwide and 
these numbers also apply to the situation in Sweden (Socialstyrelsen, 2015; WHO, 
2014). Reduced intake and use of alcohol and tobacco are suggested to reduce the 
deaths from non-communicable disease according to WHO (2014), but also a 
change towards a more healthy diet. 
 
Increased intake of dietary fibre (DF) may contribute towards a healthier diet. 
Several studies have shown associations between increased DF intake and lower 
mortality from cardiovascular disease and certain types of cancer (Kim & Je, 
2016). Studies have also consistently shown that the intake of DF lowers the risk 
for developing type-2 diabetes (Yao et al., 2014). However, the underlying mech-
anisms and causality is uncertain and further studies on the effects of DF are  
needed (Kim & Je, 2016; Yao et al., 2014). The production of short chain fatty 
acids (SCFA) by the gut microflora following DF intake and subsequent absorp-
tion and utilization of the host has been suggested as a contributor of health effects 
related with fibre intake (Lattimer & Haub, 2010).  
1.2 Short chain fatty acids- microbial products of fibre fermentation 
The gut microflora in the large intestine have an important physiological role in 
human physiology and health and consists of more than 1014 bacteria from more 
than 400 different species (Bourlioux et al., 2003). Analysis of the 16S rRNA 
from a single faecal sample have shown that 95% of the species inhabiting the 
intestinal tracts consists of the phylogenetic groups Bacteroides and Clostridium 
coccoides and the subgroup Clostridium leptum (Suau et al., 1999). Alterations of 
the microflora has been associated with several diseases, but it also affects several 
aspects of a healthy host such as organ morphogenesis, immune system matura-
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tion, metabolism and behaviour (Sommer & Backhed, 2013). One of the properties 
of the microflora is the ability to produce hydrolytic enzymes, which allows the 
microbiota to digest some of the complex carbohydrates which the human en-
zymes has no ability to degrade and proteins that have not been absorbed earlier in 
the gastrointestinal tract (Macfarlane & Macfarlane, 2012). When DF are ferment-
ed by the bacterial hydrolytic enzymes, SCFA are among the main products. 
 
SCFA are defined as straight or branched fatty acids with up to six carbons in 
length. However the definition varies and the upper limit may range between five 
and seven carbons in length (Rios-Covian et al., 2016; Bergman, 1990). Among 
SCFA, it is primarily the contents of acetic, propionic and n-butyric acid  
(Figure 1) that are affected by the DF intake (Zhao et al., 2006). These three fatty 
acids are also the main SCFA found in the large intestine (Cummings et al., 1987). 
However, iso-butyric, n-valeric, iso-valeric and caproic acid are also present in 
lower concentrations in the large intestine. 
 
Figure 1. The SCFA found in highest concentrations in the human large intestine: a) acetic acid,  
b) propionic acid and c) n-butyric acid. 
 
There is a wide range of metabolic effects of the SCFA produced in the gut and 
most of the effects can be linked to acetic, propionic and n-butyric acid 
(Macfarlane & Macfarlane, 2012). These three SCFA can be oxidized to provide 
energy and have also been shown to affect the immune system, colonic function, 
cholesterol metabolism, satiety and oxidative stress. Even if acetic acid is present 
in the highest concentrations, butyric acid seems to be of greater metabolic im-
portance followed by propionic acid. Butyric acid has been shown to have a pre-
ventive and inhibiting effect towards colonic carcinogenesis and may also affect 
obesity, insulin sensitivity and ischemic stroke (Canani et al., 2011).  
 
Overall, many animal and in vitro studies have been made regarding the produc-
tion and functions of SCFA and how they may affect human health (Canfora et al. 
(2015). However, human studies where the role of SCFA have been investigated 
in relation to clinical outcomes are largely lacking. Therefore, to draw further con-
clusion about the role of SCFA in human health more observational and interven-
tion studies in humans are needed. 
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1.3 Analysis of short chain fatty acids 
For further conclusions about the effects of SCFA, a better understanding of parti-
tioning and metabolic fates of SCFA is also needed. This requires reliable analyti-
cal methods to quantitate SCFA in different biospecimen, such as blood plasma, 
serum and faeces. Analysis of faecal SCFA has previously been performed by 
chromatography coupled with either flame ionisation (FID) or mass spectrometric 
(MS) detection (Table 1). At earlier stages, LC-MS (Liquid Chromatography Mass 
Spectrometry) was used for analysis of SCFA (Chen & Lifschitz, 1989) but more 
recent studies are using GC (Gas Chromatography) because of the high resolution 
and sensitivity it provides (Zhao et al., 2006). There are also similarities in the 
sample preparation: most methods use centrifugation at some stage to separate 
faecal water from solids and larger particles. However, the sample preparation is 
also the step where most methods differ. 
 
Table 1. Different methods used for analysis of SCFA in faecal samples with their pros and cons. 
Method Analysis Author Advantages Disadvantages 
Ultrafiltration and 
steam distillation 
LCMS and 
GC-FID 
Chen and 
Lifschitz (1989) 
Detects many 
SCFA with high 
recovery 
Time consuming 
and requires 
much equipment 
Acidification GC-FID Zhao et al. 
(2006) 
Simple method 
Detects many 
SCFA 
May contaminate 
the GC system 
easily 
Solid phase  
micro-extraction 
GC-MS Garner et al. 
(2007) 
Detects large 
amount of 
compounds 
Rapid method 
Detects few 
SCFA 
Ultracentrifugation 
and double  
derivatization steps 
GC-MS Gao et al. (2009) Detects large 
amount of 
compounds 
Detects few 
SCFA 
 
A less advanced method have been used where the faecal samples were homoge-
nized in water and acidified with hydrochloric acid followed by centrifugation 
(Zhao et al., 2006). The supernatant was then injected through glass wool onto the 
GC column. A wide array of SCFA were detected, but a possible drawback is the 
rapid contamination from non-volatile compounds in the GC column that may 
occur. An earlier method was also able to detect different SCFA through a series 
of preparations such as stomacher homogenization and ultra-filtration followed by 
GC and LC-MS (Chen & Lifschitz, 1989). However, this method was very labori-
ous, making it impractical for rapid screening of SCFA in large sample series. 
 
More recent methods using GC-MS have been able to identify a wide variety of 
compounds in faecal matter. Through a simple procedure of adsorbing volatile 
compounds with a solid-phase micro-extraction and directly injecting into a GC-
MS, it has been possible to detect SCFA and many additional compounds (Garner 
et al., 2007). Through ultracentrifugation of faecal water followed by derivatiza-
tion of the compounds by addition of ethyl chloroformate and extraction with hex-
ane, a large amount of different compounds has also been quantified in human 
faecal samples (Gao et al., 2009). However, an important fact was that major 
SCFA such as acetic and propionic acid was not analysed in any of these methods. 
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DF and SCFA have been inversely associated with several non-communicable 
diseases and other metabolic risk factors. Through the development of reliable and 
rapid methods for screening the contents of SCFA in large quantities of faecal 
samples it would be possible to further investigate these associations in interven-
tions and larger cohort studies. There are, as mentioned, a wide variety of different 
methods for analysis of SCFA content in faecal matter. However, most of these 
suffer from shortcomings such as being too time consuming, detecting too few 
SCFA or potentially exposing the column too high amounts of non-volatile com-
pounds, making the methods not qualifying as rapid screening methods.  
 
Besides the possibility to further investigate the mechanisms and potential health 
benefits of SCFA, by developing more accurate and robust SCFA methods for 
faecal samples analysis and combining the measurements with those in other bio-
specimen such as blood plasma, it may be possible to further develop risk models 
for diseases and risk factors linked to SCFA. 
1.4 Aim of the project 
The aim of this project was to develop a method for analysis of SCFA in faecal 
samples. A method recently developed by Wu et al. (manuscript) for SCFA analy-
sis in blood plasma was extended and validated for faecal samples. Faecal samples 
obtained from the Norwegian bowel cancer projects NORCCAP and BCSN were 
used within this development and validation study. To make the method applicable 
for larger screening quantities, a secondary aim was to address a combination of 
requirements: reduction or complete elimination of non-volatile compounds during 
the sample preparation while at the same time offering an ease-of-use and a rapid 
procedure for multiple sample analysis. 
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2 Methods 
2.1 Sample collection 
The Norwegian Cancer Registry is the institution under Oslo University Hospital 
Trust which collects information about all cancer cases in Norway. They are re-
sponsible for several national screening programs for cancer in Norway such as 
the Norwegian Colorectal Cancer Prevention (NORCCAP) and the Bowel Cancer 
Screening in Norway (BCSN) (Johnsen & Ursin, 2013). Samples collected during 
these two projects were analysed in this experiment.  
 
The NORCCAP study was performed between 1999 and 2001. Norwegian women 
and men (n=21 000) aged 50-64 and living in Oslo and Telemark were randomly 
chosen from the population registry (Johnsen & Ursin, 2015). They were offered a 
screening examination of the large intestine to detect cancer prevalence. Half of 
the participants were also offered an extended screening of blood and faecal sam-
ples, which were collected for further research purposes. The faecal samples from 
the NORCCAP study were stored without buffer at -25 to -30°C (Knudsen, per-
sonal communication). A randomly selected subset (n=20) of the NORCCAP fae-
cal sample set were used in the present study.  
 
The BCSN study is currently running and was built upon the NORCCAP study. In 
2012, Norwegian women and men (n=140 000) aged 50-74, living in the Norwe-
gian counties Østfold, Akershus and Buskerud, were invited to participate in the 
study (Johnsen & Ursin, 2012). The study is screening for cancer in colon and 
rectum and aims to develop improved methods for screening colorectal cancer. 
Faecal samples were collected by the participants themselves with a self-
administered kit where 10 mg faeces were added to 2 mL HEPES buffer. These 
samples were stored at -25°C (Knudsen, personal communication). For the present 
study, a randomly selected subset (n=20) of BCSN samples were analysed. Half of 
the samples were older and collected at an earlier stage compared to the rest of the 
samples.  
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Quality Control (QC) samples were collected from a 22-year old healthy male 
volunteer who did not participate in any of the Norwegian bowel cancer projects. 
The sample collection was preceded by a day of a high DF intake, consisting pre-
dominantly of whole grain products and foods rich in inulin such as onion and 
Jerusalem artichoke. Whole faecal samples were collected by the volunteer him-
self and were stored without buffer in plastic containers at -80°C. 
2.2 Chemicals, reagents and standards 
The HEPES buffer used contained 0.05 M 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES; Sigma H-3375), 0.4% bovine serum albumin (BSA; Medi-
cago, 16-0026-500), 0.095% sodium azide (Sigma-Aldrich, CAS No. 26628-22-8) 
and had pH=6.8. Acrylic acid (Sigma 147230) was used as internal standard (IS;  
4 mM acrylic acid in 16% (w/v) metaphosphoric acid (Merck no 1.00546)). Propyl 
formate (Sigma-Aldrich no W294306-1KG-K) was purified by adding 50% (w/v) 
saturated sodium carbonate water solution before use. 
 
In total, twelve different standard solutions were prepared and used for calibration. 
These standard solutions contained a mixture of seven different SCFA (Table 2) in 
concentrations ranging between 0.2-64 mM for acetic acid and 0.02-6.4 mM for 
the other six SCFA. The standard solutions were stored at +4°C.  
 
Table 2. The compounds measured throughout the experiment and added to the standard solution. 
Compound Chemical  
formula 
Molar mass 
(g/mol) 
Boiling point 
(°C) 
Manufacturer, 
product number 
Acetic acid C2H4O2 60.05 118 Merck no. 6268 
Propionic acid C3H6O2 74.08 141 Sigma no. P 1880 
iso-Butyric acid C4H8O2 88.11 155 Fluka no. 58360 
n-Butyric acid C4H8O2 88.11 164 Aldrich? no. 30.341.0 
iso-Valeric acid C5H10O2 102.13 175 Fluka no. 59850 
n-Valeric acid C5H10O2 102.13 186 Fluka no. 94530 
Capronic acid C6H12O2 116.16 206 Fluka no. 21530 
 
2.3 Sample preparation 
Samples not stored in buffer (QC samples and NORCCAP) were diluted and ho-
mogenised in HEPES buffer before analysis. A total amount of 400 mg of faecal 
matter from a QC sample was weighed into 80 ml HEPES buffer. Metal beads 
were then added and the sample was homogenised by vortexing and shaking by 
hand. The obscure yellow supernatants were aliquoted (1 mL) and stored at -25°C 
until analysis. Similarly, 6 mg fecal matter from the NORCCAP study samples 
were each weighted and put into 1.2 mL HEPES buffer. Metal beads were then 
added to the samples, which were then vortexed, after which 1 mL yellow super-
natant was further prepared for GC-MS analysis. 
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Internal standard mixture (100 µL) was added to 1 mL faecal extract (5 mg/mL 
HEPES), and vortexed for 30 seconds. Washed propyl formate (300 µL) was add-
ed and the samples were extracted by vortexing for an additional 30 seconds, fol-
lowed by centrifugation for 30 minutes at 23600 g. Approximately 100 µL of the 
clear upper organic phase was transferred to GC vials and analysed by GC-FID. 
For performance monitoring, four blank samples (containing no faecal sample) 
and four QC samples were also prepared and analysed in each sample sequence. 
2.4 Sample analysis 
The samples were analysed using the method by Wu et. al. (manuscript), here 
described briefly. Propyl formate extracts (2 µL) were injected (splitless) by a 
CTC CombiPAL autosampler (CTC analytics, Zwingen, Switzerland) onto an 
Aglient 6890N GC system equipped with a flame ionization detector (GC-FID). 
Helium was used as carrier gas (8.0 mL/min) and separation was conducted on a 
ZB-FFAP column (30 m ∗ 0.53 mm ∗ 1 µm, Phenomenex, Torrance, California). 
A straight glass liner was used in the injector and maintained at 200 °C. The oven 
was maintained at 50 °C for 2 min, ramped up to 135 °C at 20 °C/min and held for 
5 min, then ramped up to 240 °C at 30 °C/min and finally maintained for 5 min. 
The flow rates of hydrogen, air and nitrogen (makeup gas) in the FID were 30, 300 
and 30 mL/min, respectively. The temperature of the FID was 200 °C. The run 
time for each analysis was 20 min. 
 
Pure SCFA samples were analysed to obtain specific retention times for each 
SCFA, which were later used for compound identification. Standard samples were 
also extracted in the same way as faecal samples (1 mL pure standard was treated 
as 1 mL HEPES with faecal sample) and during each run, these standards were 
injected to monitor system performance and for calibration. Chromatograms were 
received from the FID, and the response (measured as area under the peaks) from 
samples and standard solutions was used for further calculations of concentrations. 
2.5 Method validation  
Validation was performed according to FDA (2001) and included testing of preci-
sion, accuracy and linearity. However, robustness testing was not performed. For 
precision, the coefficient of variation (CV) was estimated. Accuracy was assessed 
through analysis of recovery after spiking a sample with known amounts of ana-
lytes and was also evaluated by deviation from linearity of the standard curves. 
Validation was performed in three batches over three days. 
 
QC samples were spiked with 100 µL standard solution at five different levels. 
However, in the first validation batch, only STD 8,10 and 12 were used. Samples 
were prepared in triplicate and at each spiking level, samples were prepared both 
with and without faecal QC sample (Table 3). After spiking, all samples were pre-
pared similarly to ordinary samples with 100 µL acrylic acid in metaphosphoric 
acid and 300 µL propyl formate added before centrifugation and GC analysis.  
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Table 3. Experiment outline for the method validation. Concentrations are final and adjusted for the 
volume of spiking solution added. Each sample (A-L) was prepared in triplicate. 
Sample 
 
1 ml HEPES 
with faecal QC 
1 ml pure 
HEPES 
100 µl spiking 
solution 
Conc. acetic 
acid (µM) 
Conc. other 
SCFA (µM) 
A - x - 0 0 
B x - - 0 0 
C - x STD 1 20 2 
D x - STD 1 20 2 
E - x STD 3 80 8 
F x - STD 3 80 8 
G - x STD 8 400 40 
H x - STD 8 400 40 
I - x STD 10 1600 160 
J x - STD 10 1600 160 
K - x STD 12 6400 640 
L x - STD 12 6400 640 
 
Results were calculated from the chromatograms obtained. All calculations were 
made both within the batches (intra-batch measurement) and between the batches 
(inter-batch measurement). The areas of samples were normalised by the measured 
area of the IS. The areas (responsespike) of samples were then subtracted with the 
area of the baseline (responsebaseline) specific for each matrix (i.e. with or without 
QC sample). Precision, measured as CV, and the recovery were calculated using 
the formulas seen below. Example calculations can be seen in Appendix 7.1. 
 
𝐶𝐶𝐶𝐶𝐶𝐶. 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑄𝑄𝑄𝑄 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 𝑅𝑅𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑄𝑄𝑄𝑄 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 − 𝑅𝑅𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑄𝑄𝑄𝑄 𝑏𝑏𝑏𝑏𝑠𝑠𝑠𝑠𝑏𝑏𝑠𝑠𝑏𝑏𝑠𝑠  
𝐶𝐶𝐶𝐶𝐶𝐶. 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 𝑅𝑅𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 − 𝑅𝑅𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 𝑏𝑏𝑏𝑏𝑠𝑠𝑠𝑠𝑏𝑏𝑠𝑠𝑏𝑏𝑠𝑠  
 
𝑃𝑃𝑟𝑟𝑟𝑟𝑃𝑃𝑃𝑃𝑟𝑟𝑃𝑃𝑟𝑟𝑟𝑟(𝐶𝐶𝐶𝐶) = 𝑆𝑆𝑆𝑆𝐶𝐶𝑟𝑟𝑆𝑆𝐶𝐶𝑟𝑟𝑆𝑆 𝑆𝑆𝑟𝑟𝑑𝑑𝑃𝑃𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟 (𝐶𝐶𝐶𝐶𝐶𝐶. 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑄𝑄𝑄𝑄 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 1−3)
𝑀𝑀𝑟𝑟𝐶𝐶𝑟𝑟 𝑑𝑑𝐶𝐶𝐶𝐶𝑣𝑣𝑟𝑟 (𝐶𝐶𝐶𝐶𝐶𝐶. 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑄𝑄𝑄𝑄 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 1−3)  
 
𝑅𝑅𝑟𝑟𝑃𝑃𝑟𝑟𝑑𝑑𝑟𝑟𝑟𝑟𝑅𝑅 = 𝑀𝑀𝑟𝑟𝐶𝐶𝑟𝑟 𝑑𝑑𝐶𝐶𝐶𝐶𝑣𝑣𝑟𝑟 (𝐶𝐶𝐶𝐶𝐶𝐶. 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑄𝑄𝑄𝑄 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 1−3)
𝑀𝑀𝑟𝑟𝐶𝐶𝑟𝑟 𝑑𝑑𝐶𝐶𝐶𝐶𝑣𝑣𝑟𝑟 (𝐶𝐶𝐶𝐶𝐶𝐶. 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 1−3) 
 
Standard curves were constructed using the mean response of the spiked QC-
samples towards the corresponding spiking concentrations. Concentration levels 
with a CV exceeding 20% or recovery deviating more than 20% from 100% were 
excluded from the standard curves. Using the standard curves, concentrations were 
calculated (concentrationmeasured) and compared to the concentrations added (con-
centrationtrue) to calculate the deviation from linearity in accordance with the for-
mula seen below. Example calculations can be seen in Appendix 7.1. 
 
𝐷𝐷𝑟𝑟𝑑𝑑𝑃𝑃𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟 𝑓𝑓𝑟𝑟𝑟𝑟𝑓𝑓 𝐶𝐶𝑃𝑃𝑟𝑟𝑟𝑟𝐶𝐶𝑟𝑟𝑃𝑃𝑆𝑆𝑅𝑅 = 𝐶𝐶𝑟𝑟𝑟𝑟𝑃𝑃𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟𝑚𝑚𝑠𝑠𝑏𝑏𝑠𝑠𝑚𝑚𝑚𝑚𝑠𝑠𝑚𝑚 − 𝐶𝐶𝑟𝑟𝑟𝑟𝑃𝑃𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟𝑡𝑡𝑚𝑚𝑚𝑚𝑠𝑠
𝐶𝐶𝑟𝑟𝑟𝑟𝑃𝑃𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟𝑡𝑡𝑚𝑚𝑚𝑚𝑠𝑠
 
 
Using the measurements of accuracy and precision, the limits of quantification 
(LOQ) were determined. When accuracy or precision exceeded 20% (recovery 
counted as deviation from 100%), that concentration level was determined as the 
upper or lower limit of quantification (ULOQ; LLOQ) for the analyte.  
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 2.6 Distribution of SCFA in a faecal sample 
An exploratory analysis was performed to investigate the variations in SCFA con-
centration within a faecal sample. Samples were collected in four technical repli-
cates from six different positions (1-6) of a faecal sample: upper, middle and low-
er, on the inside and outside respectively (Figure 2). The samples were analysed in 
the same way as the other faecal samples. The faecal sample was collected simul-
taneously as the QC samples, but was not the same sample used for the validation. 
The difference between SCFA content between the inside and outside of the faecal 
sample was tested using unpaired, two-tailed T-test in Microsoft® Excel for Mac 
15.21 (Microsoft Corporation, Redmond, Washington). 
 
 
Figure 2. A schematic figure describing the positions of the samples collected from a single faecal 
sample. The samples were collected from a lower, middle and upper position in a peripheral position 
(sample 1-3) and the bulk (sample 4-6) respectively. (Illustration: Nils Ewald). 
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3 Results 
3.1 Method validation  
A high variability was observed between the results of the three validation batches, 
especially at the lower spiking levels (Table 4). The values of validation (recovery, 
CV and deviation from linearity) were in general higher at the lower spiking levels 
and higher during the second validation batch for all spiking levels compared to 
the the first and third batch. It was also observed that the inter-batch CV exceeded 
20% at all spiking levels, therefore this measure was excluded when determining 
LOQs for the inter-batch analysis. 
 
With the measures of accuracy and precision varying between batches, the LOQs 
also varied (Table 5-8). However, the ULOQ was relatively constant at 1280 
µmol/g for acetate and 128 µmol/g for the other SCFA respectively and R2-values 
were all close to 1. In most cases the ULOQ was determined by the lack of meas-
urements at higher concentrations, with exception for three SCFA in the second 
validation batch where the recovery deviated more than 20% from 100%. The 
LLOQ was lower during the third validation batch compared to the second, and 
the LLOQ for the first batch was only determined by lack of measurements at the 
two lower concentrations. The varied results indicate a LLOQ of 4-80 µmol/g for 
acetate respectively 0.4-8 µmol/g for the other SCFA.  
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Table 4. Summary of the validation results on three spiking levels: low (4/0.4 µmol/g faeces), medi-
um (80/8 µmol/g faeces) and high (1280/128µmol/g faeces). Recoveries are presented as deviation 
from 100%. Abbreviations: recovery (Rec), deviation from linearity (Dev) and inter-batch (Inter). 
Full results for all five spiking levels can be seen in Appendix 7.2.  
Spiking Batch  ace (%) pro (%) ibut (%) but (%) ival (%) val (%) cap (%) 
Low 2 Rec 35.8 15.2 -45.4 -345.3 -82.7 -126.0 -205.2 
  
CV 11.6 17.0 7.1 20.5 11.9 17.4 23.4 
  
Dev -176.3 23.5 357.2 1253.5 844.8 928.9 -114.1 
 
3 Rec 19.7 10.2 18.4 -10.5 24.8 -27.7 -53.1 
 
 CV 26.9 11.9 0.7 18.5 7.9 10.1 17.6 
 
 Dev -1.2 35.2 122.7 -33.1 -7.0 -10.6 -74.1 
 
Inter Rec 31.2 13.6 -10.4 -152.6 -26.5 -83.4 -142.8 
 
 CV 47.8 46.8 27.0 70.2 53.5 56.0 68.2 
 
 Dev -79.4 13.3 172.4 253.7 219.9 416.5 516.3 
Medium 1 Rec 4.5 2.3 -1.7 -12.1 -5.9 0.7 -11.7 
 
 CV 2.8 0.9 2.0 3.9 2.9 3.0 3.3 
 
 Dev -5.5 -1.5 -0.6 5.9 1.3 2.1 0.0 
 
2 Rec 4.2 2.6 -6.9 -21.8 -9.7 -14.1 -18.3 
 
 CV 1.9 3.8 1.1 4.0 1.6 1.5 2.8 
 
 Dev -6.9 -0.8 7.1 49.4 27.0 29.1 0.0 
 
3 Rec 0.4 0.1 1.6 -4.6 1.2 -3.0 -5.5 
 
 CV 1.3 1.7 0.5 1.9 0.6 0.3 0.4 
 
 Dev -2.8 -1.7 -0.6 0.7 0.3 0.4 -0.3 
 
Inter Rec 3.5 1.9 -2.8 -13.8 -5.6 -5.5 -12.7 
 
 CV 30.8 27.2 25.5 26.4 25.9 25.4 28.0 
 
 Dev -4.2 -0.4 3.2 8.9 6.1 13.4 17.6 
High 1 Rec 1.7 0.9 -1.2 -1.9 -3.5 -3.0 -5.1 
 
 CV 0.6 0.3 0.3 0.3 0.7 0.7 0.9 
 
 Dev -0.1 0.0 0.0 0.0 0.0 0.0 1.8 
 
2 Rec 5.7 1.4 -7.1 -9.5 -16.8 -18.5 -26.9 
 
 CV 6.3 1.2 6.7 7.5 13.5 14.4 19.9 
 
 Dev -0.3 0.1 0.4 0.0 0.4 0.5 -17.1 
 
3 Rec 1.2 14.8 1.3 0.6 1.2 0.8 1.0 
 
 CV 0.5 0.2 0.1 0.2 0.9 1.0 2.0 
 
 Dev 0.0 0.1 0.1 0.0 0.0 0.0 0.0 
 
Inter Rec 3.2 4.7 -2.8 -4.2 -7.5 -8.1 -12.3 
 
 CV 29.6 25.6 25.2 27.2 30.6 31.3 36.1 
  
Dev -0.2 0.0 0.2 0.1 0.3 0.2 0.3 
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Table 5. The LOQs (µmol/g faeces) determined during the first validation batch and the limiting 
factors for each LOQ. R2 is the coefficient of determination for the standard curve constructed for 
calculation of deviation from linearity. Only STD 8, 10 and 12 were used for spiking during this 
validation batch. 
 ace pro ibut but ival val cap 
LLOQ  80 8 8 8 8 8 8 
Limit - - - - - - - 
ULOQ  1280 128 128 128 128 128 128 
Limit - - - - - - - 
R2 0.999936 0.999995 0.999999 1.000000 0.999996 0.999990 1.000000 
 
Table 6. The LOQs (µmol/g faeces) determined during the second validation batch and the limiting 
factors for each LOQ. R2 is the coefficient of determination for the standard curve constructed for 
calculation of deviation from linearity 
 ace pro ibut but ival val cap 
LLOQ  16 0.4 1.6 8 8 8 1.6 
Limit Deviation Deviation Deviation Recovery Recovery Deviation Recovery 
ULOQ  1280 128 128 128 128 128 128 
Limit - - - - Recovery Recovery Recovery 
R2 0.999716 0.999991 0.999211 1.000000 0.998485 0.998240 1.000000 
 
Table 7. The LOQs (µmol/g faeces) determined during the third validation batch and the limiting 
factors for each LOQ. R2 is the coefficient of determination for the standard curve constructed for 
calculation of deviation from linearity. At the LLOQ for acetic acid. both recovery and precision 
were limiting. 
 ace pro ibut but ival val cap 
LLOQ  4 0.4 1.6 0.4 0.4 0.4 1.6 
Limit Rec, Pre Deviation Deviation Precision Recovery Recovery Recovery 
ULOQ  1280 128 128 128 128 128 128 
Limit - - - - - - - 
R2 0.999989 0.999988 0.999963 0.999999 1.000000 1.000000 1.000000 
 
Table 8. The LOQs (µmol/g faeces) determined during the inter- batch validation analysis and the 
limiting factors for each LOQ. R2 is the coefficient of determination for the standard curve con-
structed for calculation of deviation from linearity. The CV exceeded 20% for all concentration 
levels in the inter-batch validation, therefore the LOQs were only determined using the accuracy 
measurements. 
 ace pro ibut but ival val cap 
LLOQ  16 0.4 1.6 1.6 1.6 1.6 8 
Limit Deviation - Deviation Recovery Deviation Recovery Deviation 
ULOQ  1280 128 128 128 128 128 128 
Limit - - - - - - - 
R2 0.999892 0.999999 0.999867 0.999836 0.999669 0.999628 0.999358 
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 3.2 Distribution of SCFA in a faecal sample 
Mean values were calculated for the concentrations measured at each position. A 
low standard deviation was observed and overall, the contents were higher on the 
inside than the the surface and some differences were seen between the lower, 
middle and upper positions (Table 9). The T-test showed a significant difference 
between the inside and surface of the faecal sample (Table 9). It was not possible 
to perform an ANOVA comparing the three longitudinal positions due to the low 
amount of samples taken and the fact that the samples from each position were 
technical replicates.  
 
Table 9. Mean concentrations (µmol/g faeces) and standard deviations on six different positions of a 
faecal sample. The resulting P-values from the T-test comparing the contents of the in- and outside 
are presented below. 
Position  ace pro ibut nbut ival nval cap 
1 Mean 126.8 25.5 3.2 27.3 4.1 5.4 5.5 
 SD 0.81 0.02 0.02 0.16 0.02 0.04 0.06 
2 Mean 121.0 25.7 3.5 28.3 4.7 5.6 5.2 
 SD 0.23 0.05 0.01 0.14 0.01 0.03 0.02 
3 Mean 115.0 22.2 2.8 22.4 3.6 4.6 5.0 
 SD 0.90 0.09 0.01 0.17 0.02 0.02 0.04 
4 Mean 133.8 31.0 3.9 43.3 5.3 6.9 7.5 
 SD 1.19 0.45 0.01 0.56 0.03 0.02 0.02 
5 Mean 139.7 34.6 4.5 51.4 6.0 7.9 8.8 
 SD 0.70 0.29 0.02 0.13 0.03 0.04 0.07 
6 Mean 141.4 34.8 4.6 51.7 6.2 8.1 9.1 
 SD 0.79 0.30 0.01 0.12 0.04 0.03 0.03 
T-test P-value 0.0176 0.0062 0.0132 0.0039 0.0151 0.0074 0.0153 
 
3.3 SCFA concentrations in NORCCAP and BCSN samples 
Three kinds of faecal samples were analysed; samples in the NORCCAP study 
stored without buffer and older respectively newer samples collected in the BCSN 
study stored in HEPES buffer. Boxplots were constructed (Figure 3) and a one-
way ANOVA was performed using SAS® 9.4 (SAS Institute Inc., North Carolina, 
US) to compare the concentrations of the different sample types. One test was 
made using two levels: NORCCAP and BCSN samples, and one test was made 
with three levels: NORCCAP samples and older and newer BCSN samples. How-
ever, no significant differences were observed in any of the tests for any SCFA. 
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Figure 3. Boxplots describing the SCFA concentrations measured throughout the analysis of 
NORCCAP and BCSN samples. The stars (*) marks the outliers identified. Abbreviations used: NC 
(NORCCAP samples), BO (old BCSN samples) and BN (new BCSN samples). 
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4 Discussion 
The validation showed that the method used was useful for quantification of seven 
SCFA in faecal samples within the range determined by the LOQs. With the sam-
ple preparation taking approximately four hours for 40 samples and the GC-FID 
analysis 20 minutes per sample, the method can be regarded as a rapid method 
suitable for screening of larger number of samples. 
 
The ULOQ was similar between batches. In general, the accuracy and precision 
ranged between 0-10% at the highest concentration level with a few exceptions. 
This indicates that it may be possible to expand the quantification range upwards 
by analysing higher concentration levels. The coefficient of determination (R2) 
was another factor with low variability and was in all cases close to the number 1 
with only a few thousands in difference. This shows high linearity of the standard 
samples. However, with only five standard samples used at its highest, the R2-
value is expected to be very close to 1. 
 
The concentration level of the LLOQ varied more between the validation batches: 
for acetate it ranged between 4-80 µmol/g faeces and for other SCFA it ranged 
between 0.4-8 µmol/g. The reason for this variation is partly explained by the first 
validation batch, where the two lower spiking levels were not analysed. It was also 
observed that the values of accuracy and precision was much higher in the second 
validation batch compared to other batches. This may have been caused handling 
errors throughout the experiment. If a more experienced person would carry out 
the validation it is possible that lower values of accuracy and precision would be 
achieved and the results between the batches would be more similar.  
 
Even though the lowest LLOQs would be assumed (4, 0.4 and 1.6 µmol/g respec-
tively), the sensitivity of the method is somewhat limited compared with an earlier 
method developed by Zhao et al. (2006). However, the concentrations measured in 
the BCSN and NORCCAP samples were within the LOQs for all SCFA with ex-
ception for iso-butyric acid and caproinc acid. With exception for these two 
SCFA, this proves the applicability of the method for physiologically relevant 
concentrations. It would be desirable to further expand the range of quantification 
for the method though, especially for iso-butyric and capronic acid.  
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Comparing with other methods, a distinguishable difference is the amount of sam-
ples used for analysis. In other methods (Zhao et al., 2006; Chen & Lifschitz, 
1989), 0.1 to 0.2 g of faecal sample is added per mL solvent in the initial steps of 
the experiment. By increasing the concentration of faecal sample analysed, it is 
possible that a higher sensitivity and a lower LLOQ could be achieved, which has 
also been suggested in earlier methods for SCFA analysis (Arellano et al., 2000).  
 
The inter-batch CV exceeded 20% for all SCFA when comparing the batches, a 
problem which was neither observed in the recovery nor deviation from linearity. 
This may indicate that the response within each batch are on the same relative 
levels, but between the batches the response differs, thus giving a high CV. It is 
possible that the column of the GC successively has been contaminated, indicating 
that the aim to reduce or eliminate non-volatile compounds was not fulfilled. An-
other possible explanation though, is the organic solvent used. A new bottle of 
washed propyl formate was taken into use before the third validation batch. A 
distinctly higher amount of upper phase as observed during this batch compared to 
earlier batches. A larger volume of organic phase would explain the lower re-
sponse seen in the third validation batch compared to the two earlier batches, as a 
result of a more diluted sample. The purity of the washed propyl formate therefore 
seems to have a significant role for the formation of phases, which should be heav-
ily considered for further analysis to achieve comparable results. 
 
Before applying the method in further studies, additional validation analysis 
should preferably be carried out. After increasing the amount of faeces used in the 
method, the lower concentrations should be examined throughoutly once again. To 
expand the range of quantification towards higher concentrations, QC samples 
should also be spiked with higher SCFA concentrations.  
 
The SCFA distribution test showed a significantly higher content of all seven 
SCFA on the inside compared to the outside of the faecal sample. Colonic SCFA 
is rapidly absorbed by the epithelial cells in the colorectal region of the intestine 
with only 5-10% of the produced amounts remaining in the faeces (Canfora et al., 
2015). Since the SCFA of the peripheral parts of the faeces naturally are more 
easily accessible, these are also more rapidly absorbed, which may be the reason 
for the observed difference between the in- and outside. The volatility of SCFA 
may also contribute, since the SCFA of the outside of the faeces are more prone to 
evaporation than those on the inside.  
 
Even though the analysis was performed on a single faecal sample it may give 
important information about the characteristics of faecal matter. The analysis 
clearly shows that a single aliquot of faecal sample may not be representative for 
the whole faecal sample with respect to the SCFA content. To reduce error terms 
from sampling location, homogenization of the faecal sample before analysis 
would therefore be ideal. This may not always be possible, however. The second 
best opinion would then be consistent sampling from the same position of all sam-
ples, which may also be difficult, since faeces will vary in shape and consistence. 
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No earlier evidence has been found regarding the distribution of SCFA or metabo-
lites in general in faecal samples. To further investigate the case, analysis of sam-
ples from a large variety of individuals is suggested. Biological replicates within 
each position is also suggested to make further statistical analysis possible regard-
ing both inner and outer position, but also the longitudinal position. This way it 
would be possible to make more accurate measurements and obtain comparable 
results regarding SCFA in faeces. 
 
The SCFA concentrations measured in the Norwegian cancer project faecal sam-
ples shows large variability, which is to be expected from a free-living population. 
Compared to another study (Hoverstad et al., 1984) earlier performed on a Nor-
wegian population (n=20), the SCFA concentrations lies within the same range. 
This further indicates that the method used in this project is valid for the concen-
trations which were measured. Another study (McOrist et al., 2008) carried out on 
a small Australian population (n=8), also provides similar results regarding the 
concentrations. However, this study should not be seen as fully comparable, since 
it has been shown that the SCFA contents in faeces are significantly different be-
tween ethnical groups (Segal et al., 1995). 
 
NORCCAP samples were collected more than 15 years ago, and due to the volatil-
ity of SCFA it is likely that some SCFA have evaporated during storage. However, 
there is no evidence of systematically lower concentrations in these samples com-
pared to the more recently collected BCSN samples, which makes this hypothesis 
less plausible. In some cases, the NORCCAP samples seem to contain even a 
higher amount of SCFA than the BCSN samples. During sampling it was observed 
that some NORCCAP samples were very dry, which indicates that water may have 
evaporated during the storage, giving a higher concentration of SCFA. However, 
the ANOVA performed showed no significant difference between the different 
sample types to support this theory. 
 
When analysing the BCSN samples, it was also apparent that the volume had re-
duced from the original sample addition to the vials. This represents a considerable 
problem first because it hints at poor storage stability either of the samples or in 
the applied protocol. If the volume reduction was the result of solvent evaporation, 
the contents will also be more concentrated giving a systematic but unquantifiable 
bias. In some cases, the caproic acid concentrations for BCSN samples reached 
negative concentrations. A possible explanation is that the HEPES buffer used for 
storage was different from the one used for blank samples since they were pro-
duced in Norway and Sweden respectively. If this method is to be further devel-
oped, it would be essential to investigate thoroughly the effects of storage with and 
without HEPES buffer, and to use the same buffer in storage and analysis. 
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5 Conclusion 
The aim of this project was to develop a rapid and ease-of-use method for analysis 
of SCFA contents in faecal samples, which was also achieved. The validation of 
the method presented showed varying results, but for most SCFA the limits of 
quantification included the physiologically relevant concentrations. The explorato-
ry test performed regarding the distribution of SCFA contents in faecal matter 
implicates that homogenisation and the position when sampling is of importance 
due to the differences seen between the in- and outside of the faeces. Results ob-
tained from the NORCCAP and BCSN faecal samples is consistent with earlier 
reports, indicating that the concentrations measured with the method are within the 
correct range. However, before further application of the method, additional vali-
dation is proposed. A larger amount of faeces should preferably be added to the 
method, the lower concentrations should be examined once again, and higher con-
centration levels should also be investigated. A further investigation is also pro-
posed regarding the storage stability with and without HEPES buffer.  
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7 Appendix 
7.1 Example calculations 
 
Table A1. Responses for acetic acid and IS from the chromatogram of the third validation 
batch. A and B samples are on baseline (non-spiked), C and D are spiked with STD 1 (4 
µmol/g faeces) and E and F are spiked with STD 3 (16 µmol/g faeces). A, C and E con-
tains only HEPES, no QC, sample. B, D and F contains QC sample. 
Sample A1 A2 A3 B1 B2 B3 C1 C2 C3 
Acetic acid 9.8 9 9.1 58.8 56.6 57 12.2 12.2 12.4 
IS 346.4 360.9 356.4 360.2 345.4 347.7 339.7 341.1 362.3 
Sample D1 D2 D3 E1 E2 E3 F1 F2 F3 
Acetic acid 58.8 59.4 59.4 21 20.9 20.8 68.3 69.2 68.3 
IS 345.7 343 350.3 350.5 350.3 347.2 352.1 352.7 353.1 
 
1. A mean value was calculated for all IS responses. 
 
𝐼𝐼𝑆𝑆𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏 = 358.2 
 
2. All responses were normalised towards the IS of the respective sample and mul-
tiplicities with the ISmean. Example for D1:  
 
𝐷𝐷1 𝐼𝐼𝑆𝑆𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏 ∗ 𝐼𝐼𝑆𝑆𝐷𝐷1⁄                        58.8 346.4 ∗ 345.7 = 60.0⁄  
 
3. Mean values were calculated for the calibrated baseline samples (A and B). 
  
𝐴𝐴𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏 = 9.4              𝐵𝐵𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏 = 58.7 
 
4. Responses for spiked samples were subtracted with the baseline means for the 
specific matrix, spiked HEPES samples with Amean and spiked QC samples with 
Bmean. Example for D1: 
 
𝐷𝐷1 − 𝐵𝐵𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏                       61.0 − 58.7 = 2.3 
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5. Mean values were calculated for each each spiking level and matrix. 
 
𝐶𝐶𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏 = 3.2              𝐷𝐷𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏 = 2.6 
 
6. The recovery was calculated by dividing the corrected mean response for the 
spiked QC sample with the spiked HEPES sample. The recovery was subtracted 
from 1. Example for D-samples: 
 
𝑅𝑅𝑟𝑟𝑃𝑃𝑟𝑟𝑑𝑑𝑟𝑟𝑟𝑟𝑅𝑅 = 1 − (𝐷𝐷𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏 𝐶𝐶𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏)⁄  
 1 − (2.6 3.2)⁄ = 0.197 = 𝟏𝟏𝟏𝟏.𝟕𝟕% 
 
7. The CV was calculated by dividing the standard deviation (SD) for the correct-
ed response for each spiking level with the mean value for the responses. Example 
for D-samples: 
 
𝐶𝐶𝐶𝐶 = 𝑆𝑆𝐷𝐷(𝐷𝐷1−3)/𝑀𝑀𝑟𝑟𝐶𝐶𝑟𝑟(𝐷𝐷1−3) 
 0.7/2.6 = 0.269 = 𝟐𝟐𝟐𝟐.𝟏𝟏% 
 
8. Standard curves (figure A1) were constructed for each SCFA were the mean 
values (x) for each spiking level was plotted towards the corresponding concentra-
tion (y). Spiking levels with recovery or precision exceeding 20% were excluded 
from the standard curve. The equation and R2-value were noted. 
 
 
Figure A1. The standard curve for acetic acid made from the mean values of calibrated 
response plotted towards the corresponding concentrations. 
 
9. The equation for the x value was calculated. 
 
𝑅𝑅 = 137 879𝑥𝑥 − 0.1201 
 
𝑥𝑥 = (𝑅𝑅 − 0.1201)/137 879 
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10. Using the re-calculated equation from the standard curve, a concentration was 
calculated for each mean response value. Example for E-samples: 
 
𝐸𝐸𝑚𝑚𝑠𝑠𝑏𝑏𝑏𝑏 = 11.1 
 
𝐶𝐶𝑟𝑟𝑟𝑟𝑃𝑃𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟𝐻𝐻 = (11.1 − 0.1201)/137 879 = 8.1 ∗ 10−5 
 
11. The calculated concentration was subtracted with the true concentration and 
divided by the same concentration to calculate the deviation from linearity. 
 
𝐶𝐶𝑟𝑟𝑟𝑟𝑃𝑃𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟𝑇𝑇𝑚𝑚𝑚𝑚𝑠𝑠 𝐻𝐻 = 8 ∗ 105 
 
𝐷𝐷𝑟𝑟𝑑𝑑𝑃𝑃𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟 𝑓𝑓𝑟𝑟𝑟𝑟𝑓𝑓 𝐶𝐶𝑃𝑃𝑟𝑟𝑟𝑟𝐶𝐶𝑟𝑟𝑃𝑃𝑆𝑆𝑅𝑅 = (𝐶𝐶𝑟𝑟𝑟𝑟𝑃𝑃𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟𝐻𝐻 − 𝐶𝐶𝑟𝑟𝑟𝑟𝑃𝑃𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟𝑡𝑡𝑚𝑚𝑚𝑚𝑠𝑠)/𝐶𝐶𝑟𝑟𝑟𝑟𝑃𝑃𝑟𝑟𝑟𝑟𝑆𝑆𝑟𝑟𝐶𝐶𝑆𝑆𝑃𝑃𝑟𝑟𝑟𝑟𝑡𝑡𝑚𝑚𝑚𝑚𝑠𝑠 
 (8.1 ∗ 105 − 8 ∗ 105)/8 ∗ 105 = 0.0141 = 𝟏𝟏.𝟒𝟒𝟏𝟏% 
7.2 Validation results 
 
Table A2. Results for each spiking level from the first validation batch. The mean responses are 
normalised towards IS and the baseline sample. Calculated concentration are given by standard 
curve. 
STD 8 ace pro ibut but ival val cap 
Mean response 98.6 59.5 191.7 207.0 395.4 410.1 644.7 
Calc. conc (µM) 377.9 39.4 39.8 42.4 40.5 40.9 40.0 
True conc (µM) 400 40 40 40 40 40 40 
Recovery (%) 4.5 2.3 -1.7 -12.1 -5.9 0.7 -11.7 
CV (%) 2.8 0.9 2.0 3.9 2.9 3.0 3.3 
Deviation (%) -5.5 -1.5 -0.6 5.9 1.3 2.1 0.0 
STD 10 ace pro ibut but ival val cap 
Mean response 411.9 238.5 758.3 745.5 1519.3 1597.2 2401.5 
Calc. conc (µM) 1627.6 160.8 160.3 160.0 159.3 158.9 160.0 
True conc (µM) 1600 160 160 160 160 160 160 
Recovery (%) 2.4 1.6 2.1 -2.5 -3.6 -2.0 -6.0 
CV (%) 1.4 1.4 3.3 1.3 0.7 0.7 0.9 
Deviation (%) 1.7 0.5 0.2 0.0 -0.4 -0.7 0.0 
STD 12 ace pro ibut but ival val cap 
Mean response 1607.2 945.1 3013.2 2943.0 6068.6 6436.2 9599.6 
Calc. conc (µM) 6394.5 639.9 639.9 640.0 640.1 640.2 651.7 
True conc (µM) 6400 640 640 640 640 640 640 
Recovery (%) 1.7 0.9 -1.2 -1.9 -3.5 -3.0 -5.1 
CV (%) 0.6 0.3 0.3 0.3 0.7 0.7 0.9 
Deviation (%) -0.1 0.0 0.0 0.0 0.0 0.0 1.8 
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Table A3. Results for each spiking level from the second validation batch. The mean responses are 
normalised towards IS and the baseline sample. Calculated concentration are given by standard 
curve 
STD 1 ace pro ibut but ival val cap 
Mean response 5.3 3.5 12.6 48.3 34.1 41.5 86.3 
Calc. conc (µM) -15.3 2.5 9.1 27.1 18.9 20.6 -0.3 
True conc (µM) 20 2 2 2 2 2 2 
Recovery (%) 35.8 15.2 -45.4 -345.3 -82.7 -126.0 -205.2 
CV (%) 11.6 17.0 7.1 20.5 11.9 17.4 23.4 
Deviation (%) -176.3 23.5 357.2 1253.5 844.8 928.9 -114.1 
STD 3 ace pro ibut but ival val cap 
Mean response 20.8 12.8 39.4 70.4 92.8 102.7 176.4 
Calc. conc (µM) 50.4 8.8 14.5 31.2 24.0 25.5 5.9 
True conc (µM) 80 8 8 8 8 8 8 
Recovery (%) 15.9 -3.1 -15.5 -74.8 -22.3 -39.3 -53.6 
CV (%) 7.6 6.0 6.7 28.5 13.3 15.7 20.8 
Deviation (%) -37.0 9.6 80.9 290.5 199.5 218.6 -26.0 
STD 8 ace pro ibut but ival val cap 
Mean response 96.9 58.7 182.3 221.5 403.7 428.6 671.1 
Calc. conc (µM) 372.4 39.7 42.8 59.8 50.8 51.6 40.0 
True conc (µM) 400 40 40 40 40 40 40 
Recovery (%) 4.2 2.6 -6.9 -21.8 -9.7 -14.1 -18.3 
CV (%) 1.9 3.8 1.1 4.0 1.6 1.5 2.8 
Deviation (%) -6.9 -0.8 7.1 49.4 27.0 29.1 0.0 
STD 10 ace pro ibut but ival val cap 
Mean response 404.2 235.4 711.3 752.4 1512.7 1597.8 2413.4 
Calc. conc (µM) 1673.5 158.7 147.9 160.0 146.5 145.5 160.0 
True conc (µM) 1600 160 160 160 160 160 160 
Recovery (%) -0.3 -1.4 -4.3 -6.4 -6.0 -7.0 -8.7 
CV (%) 2.3 2.2 1.1 1.5 0.9 0.9 0.7 
Deviation (%) 4.6 -0.8 -7.5 0.0 -8.4 -9.1 0.0 
STD 12 ace pro ibut but ival val cap 
Mean response 1516.9 949.9 3202.4 3294.8 7261.8 7797.5 12465.4 
Calc. conc (µM) 6383.8 640.3 642.8 640.0 642.7 642.9 530.8 
True conc (µM) 6400 640 640 640 640 640 640 
Recovery (%) 5.7 1.4 -7.1 -9.5 -16.8 -18.5 -26.9 
CV (%) 6.3 1.2 6.7 7.5 13.5 14.4 19.9 
Deviation (%) -0.3 0.1 0.4 0.0 0.4 0.5 -17.1 
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Table A4. Results for each spiking level from the third validation batch. The mean responses are 
normalised towards IS and the baseline sample. Calculated concentration are given by standard 
curve. 
STD 1 ace pro ibut but ival val cap 
Mean response 2.6 1.8 8.6 16.3 15.4 18.0 30.1 
Calc. conc (µM) 19.8 2.7 4.5 1.3 1.9 1.8 0.5 
True conc (µM) 20 2 2 2 2 2 2 
Recovery (%) 19.7 10.2 18.4 -10.5 24.8 -27.7 -53.1 
CV (%) 26.9 11.9 0.7 18.5 7.9 10.1 17.6 
Deviation (%) -1.2 35.2 122.7 -33.1 -7.0 -10.6 -74.1 
STD 3 ace pro ibut but ival val cap 
Mean response 11.1 7.4 25.3 35.7 51.6 56.2 86.1 
Calc. conc (µM) 81.1 8.9 10.0 8.0 7.9 7.9 6.7 
True conc (µM) 80 8 8 8 8 8 8 
Recovery (%) 8.1 0.9 10.6 -10.8 6.1 -11.3 -20.7 
CV (%) 4.8 6.5 8.6 0.6 1.0 1.3 2.3 
Deviation (%) 1.4 11.1 24.6 0.0 -0.9 -1.6 -15.8 
STD 8 ace pro ibut but ival val cap 
Mean response 53.5 35.1 115.5 129.9 243.5 259.3 384.5 
Calc. conc (µM) 388.8 39.3 39.8 40.3 40.1 40.1 39.9 
True conc (µM) 400 40 40 40 40 40 40 
Recovery (%) 0.4 0.1 1.6 -4.6 1.2 -3.0 -5.5 
CV (%) 1.3 1.7 0.5 1.9 0.6 0.3 0.4 
Deviation (%) -2.8 -1.7 -0.6 0.7 0.3 0.4 -0.3 
STD 10 ace pro ibut but ival val cap 
Mean response 222.2 143.7 472.7 478.2 958.2 1013.2 1466.7 
Calc. conc (µM) 1612.5 158.8 157.7 159.6 159.9 160.0 160.1 
True conc (µM) 1600 160 160 160 160 160 160 
Recovery (%) -1.3 -0.9 2.9 0.7 5.0 4.1 5.7 
CV (%) 1.4 0.9 0.8 0.9 1.3 1.4 2.2 
Deviation (%) 0.8 -0.8 -1.4 -0.2 0.0 0.0 0.1 
STD 12 ace pro ibut but ival val cap 
Mean response 882.0 581.9 1934.9 1880.2 3821.3 4033.1 5785.2 
Calc. conc (µM) 6397.5 640.3 640.6 640.1 640.0 640.0 640.0 
True conc (µM) 6400 640 640 640 640 640 640 
Recovery (%) 1.2 14.8 1.3 0.6 1.2 0.8 1.0 
CV (%) 0.5 0.2 0.1 0.2 0.9 1.0 2.0 
Deviation (%) 0.0 0.1 0.1 0.0 0.0 0.0 0.0 
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Table A5. Results for each spiking level from inter-batch validation. The mean responses are nor-
malised towards IS and the baseline sample. Calculated concentration are given by standard curve. 
STD 1 ace pro ibut but ival val cap 
Mean response 3.9 2.6 10.6 32.3 24.7 29.7 58.2 
Calc. conc (µM) 4.1 2.3 5.4 7.1 6.4 10.3 12.3 
True conc (µM) 20 2 2 2 2 2 2 
Recovery (%) 31.2 13.6 -10.4 -152.6 -26.5 -83.4 -142.8 
CV (%) 47.8 46.8 27.0 70.2 53.5 56.0 68.2 
Deviation (%) -79.4 13.3 172.4 253.7 219.9 416.5 516.3 
STD 3 ace pro ibut but ival val cap 
Mean response 15.9 10.1 32.4 53.1 72.2 79.5 131.2 
Calc. conc (µM) 61.6 8.1 10.6 12.0 11.7 15.5 17.3 
True conc (µM) 80 8 8 8 8 8 8 
Recovery (%) 13.3 -1.6 -3.7 -46.4 -10.4 -27.9 -41.0 
CV (%) 43.1 38.1 31.0 46.3 40.4 41.3 48.7 
Deviation (%) -23.0 0.8 32.0 50.0 46.2 93.8 116.4 
STD 8 ace pro ibut but ival val cap 
Mean response 83.0 51.1 163.2 186.1 347.5 366.0 566.8 
Calc. conc (µM) 383.2 39.8 41.3 43.5 42.4 45.3 47.0 
True conc (µM) 400 40 40 40 40 40 40 
Recovery (%) 3.5 1.9 -2.8 -13.8 -5.6 -5.5 -12.7 
CV (%) 30.8 27.2 25.5 26.4 25.9 25.4 28.0 
Deviation (%) -4.2 -0.4 3.2 8.9 6.1 13.4 17.6 
STD 10 ace pro ibut but ival val cap 
Mean response 346.1 205.9 647.4 658.7 1330.1 1402.8 2093.8 
Calc. conc (µM) 1645.3 159.8 155.0 155.6 152.1 153.3 151.2 
True conc (µM) 1600 160 160 160 160 160 160 
Recovery (%) 0.6 -0.1 0.0 -3.1 -2.2 -2.3 -4.0 
CV (%) 31.0 26.1 23.7 23.7 24.2 24.0 25.9 
Deviation (%) 2.8 -0.1 -3.1 -2.8 -4.9 -4.2 -5.5 
STD 12 ace pro ibut but ival val cap 
Mean response 1335.4 825.6 2716.8 2706.0 5717.2 6089.0 9283.4 
Calc. conc (µM) 6390.0 640.1 641.1 640.9 641.8 641.3 641.8 
True conc (µM) 6400 640 640 640 640 640 640 
Recovery (%) 3.2 4.7 -2.8 -4.2 -7.5 -8.1 -12.3 
CV (%) 29.6 25.6 25.2 27.2 30.6 31.3 36.1 
Deviation (%) -0.2 0.0 0.2 0.1 0.3 0.2 0.3 
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